{"address1": "37000 Grand River Avenue", "address2": "Suite 120", "city": "Farmington Hills", "state": "MI", "zip": "48335", "country": "United States", "phone": "248 957 9024", "website": "https://opusgtx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.", "companyOfficers": [{"maxAge": 1, "name": "Mr. George  Magrath M.B.A., M.D., M.S.", "age": 40, "title": "CEO & Director", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 625071, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bernhard  Hoffmann M.B.A.", "age": 68, "title": "Senior Vice President of Corporate Development & Secretary", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 434100, "exercisedValue": 0, "unexercisedValue": 152634}, {"maxAge": 1, "name": "Ms. Amy  Zaremba Rabourn C.P.A., MAcc", "age": 43, "title": "Senior Vice President of Finance", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 434100, "exercisedValue": 0, "unexercisedValue": 31371}, {"maxAge": 1, "name": "Dr. Benjamin R. Yerxa Ph.D.", "age": 58, "title": "President & Director", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nirav Suresh  Jhaveri C.F.A.", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joseph K. Schachle MBA", "age": 59, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashwath  Jayagopal Ph.D.", "age": 42, "title": "Chief Scientific & Development Officer", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Bindu  Manne", "title": "Head of Market Development & Commercialization", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Erik  Sims", "title": "Director & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://www.rexahn.com/cms/index.php/investor-relations/", "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.9818, "open": 0.986, "dayLow": 0.886, "dayHigh": 1.0002, "regularMarketPreviousClose": 0.9818, "regularMarketOpen": 0.986, "regularMarketDayLow": 0.886, "regularMarketDayHigh": 1.0002, "payoutRatio": 0.0, "forwardPE": -1.0581396, "volume": 224688, "regularMarketVolume": 224688, "averageVolume": 207530, "averageVolume10days": 374260, "averageDailyVolume10Day": 374260, "bid": 0.8677, "ask": 0.9307, "bidSize": 2, "askSize": 1, "marketCap": 40917880, "fiftyTwoWeekLow": 0.81, "fiftyTwoWeekHigh": 2.22, "priceToSalesTrailing12Months": 3.7225146, "fiftyDayAverage": 1.0752, "twoHundredDayAverage": 1.28685, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 17252938, "profitMargins": 0.0, "floatShares": 28172172, "sharesOutstanding": 44964700, "sharesShort": 685446, "sharesShortPriorMonth": 672994, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0217, "heldPercentInsiders": 0.14097, "heldPercentInstitutions": 0.17575, "shortRatio": 5.18, "shortPercentOfFloat": 0.0227, "impliedSharesOutstanding": 44964700, "bookValue": 0.213, "priceToBook": 4.2723007, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -57532000, "trailingEps": -1.09, "forwardEps": -0.86, "lastSplitFactor": "1:4", "lastSplitDate": 1604620800, "enterpriseToRevenue": 1.57, "enterpriseToEbitda": -0.506, "52WeekChange": -0.53092784, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.91, "targetHighPrice": 15.0, "targetLowPrice": 8.0, "targetMeanPrice": 10.33333, "targetMedianPrice": 8.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 30323000, "totalCashPerShare": 0.96, "ebitda": -34068000, "totalDebt": 0, "quickRatio": 3.196, "currentRatio": 3.241, "totalRevenue": 10992000, "revenuePerShare": 0.411, "returnOnAssets": -0.46903, "returnOnEquity": -1.52457, "grossProfits": 10992000, "revenueGrowth": 1.544, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -2.33124, "financialCurrency": "USD", "symbol": "IRD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NCM", "messageBoardId": "finmb_560534013", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "regularMarketTime": 1743537600, "regularMarketChangePercent": -7.3130975, "regularMarketPrice": 0.91, "shortName": "Opus Genetics, Inc.", "longName": "Opus Genetics, Inc.", "marketState": "PRE", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1131633000000, "regularMarketChange": -0.07179999, "regularMarketDayRange": "0.886 - 1.0002", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 207530, "fiftyTwoWeekLowChange": 0.100000024, "fiftyTwoWeekLowChangePercent": 0.12345682, "fiftyTwoWeekRange": "0.81 - 2.22", "fiftyTwoWeekHighChange": -1.31, "fiftyTwoWeekHighChangePercent": -0.59009004, "fiftyTwoWeekChangePercent": -53.092785, "dividendDate": 1604620800, "earningsTimestamp": 1743423626, "earningsTimestampStart": 1746707400, "earningsTimestampEnd": 1747053000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.09, "epsForward": -0.86, "epsCurrentYear": -1.015, "priceEpsCurrentYear": -0.8965518, "fiftyDayAverageChange": -0.16519994, "fiftyDayAverageChangePercent": -0.15364578, "twoHundredDayAverageChange": -0.37684995, "twoHundredDayAverageChangePercent": -0.29284683, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Ocuphire Pharma, Inc.", "nameChangeDate": "2025-04-01", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "Opus Genetics", "trailingPegRatio": null}